Moderna to Present at Upcoming Conferences in November 2024
Moderna (NASDAQ:MRNA) has announced its participation in three major healthcare conferences in November 2024. The company will present at the Guggenheim's Inaugural Healthcare Innovation Conference on November 12th at 10:00am ET, the UBS Global Healthcare Conference on November 13th at 3:30pm PT, and the Jefferies London Healthcare Conference on November 21st at 2:00pm GT. Live webcasts of all presentations will be accessible through the Investors section of Moderna's website, with replays available for at least 30 days after each event.
Moderna (NASDAQ:MRNA) ha annunciato la sua partecipazione a tre importanti conferenze sanitarie nel novembre 2024. L'azienda presenterà al Guggenheim's Inaugural Healthcare Innovation Conference il 12 novembre alle 10:00 ET, alla UBS Global Healthcare Conference il 13 novembre alle 15:30 PT, e alla Jefferies London Healthcare Conference il 21 novembre alle 14:00 GT. Le trasmissioni in diretta di tutte le presentazioni saranno accessibili nella sezione Investitori del sito di Moderna, con repliche disponibili per almeno 30 giorni dopo ogni evento.
Moderna (NASDAQ:MRNA) ha anunciado su participación en tres importantes conferencias de salud en noviembre de 2024. La empresa presentará en la Guggenheim's Inaugural Healthcare Innovation Conference el 12 de noviembre a las 10:00 ET, en la UBS Global Healthcare Conference el 13 de noviembre a las 15:30 PT, y en la Jefferies London Healthcare Conference el 21 de noviembre a las 14:00 GT. Las transmisiones en vivo de todas las presentaciones estarán disponibles en la sección de Inversores del sitio web de Moderna, con repeticiones accesibles durante al menos 30 días después de cada evento.
모더나 (NASDAQ:MRNA)는 2024년 11월에 있을 세 가지 주요 헬스케어 회의에 참여한다고 발표했습니다. 회사는 11월 12일 오전 10시 ET에 구겐하임의 첫 헬스케어 혁신 회의에서 발표하며, 11월 13일 오후 3시 30분 PT에 UBS 글로벌 헬스케어 회의에서, 11월 21일 오후 2시 GT에 제퍼리스 런던 헬스케어 회의에서 발표할 예정입니다. 모든 발표의 라이브 웹캐스트는 모더나 웹사이트의 투자자 섹션을 통해 접속할 수 있으며, 각 이벤트 종료 후 최소 30일 동안 재방송이 가능합니다.
Moderna (NASDAQ:MRNA) a annoncé sa participation à trois grandes conférences sanitaires en novembre 2024. La société présentera lors de la Guggenheim's Inaugural Healthcare Innovation Conference le 12 novembre à 10h00 ET, à la UBS Global Healthcare Conference le 13 novembre à 15h30 PT, et à la Jefferies London Healthcare Conference le 21 novembre à 14h00 GT. Des webdiffusions en direct de toutes les présentations seront accessibles dans la section Investisseurs du site web de Moderna, avec des rediffusions disponibles pendant au moins 30 jours après chaque événement.
Moderna (NASDAQ:MRNA) hat seine Teilnahme an drei wichtigen Gesundheitskonferenzen im November 2024 angekündigt. Das Unternehmen wird am 12. November um 10:00 Uhr ET auf der Guggenheim's Inaugural Healthcare Innovation Conference, am 13. November um 15:30 Uhr PT auf der UBS Global Healthcare Conference und am 21. November um 14:00 Uhr GT auf der Jefferies London Healthcare Conference präsentieren. Live-Übertragungen aller Präsentationen sind im Investorenbereich der Moderna-Website verfügbar, wobei Wiederholungen für mindestens 30 Tage nach jeder Veranstaltung verfügbar sind.
- None.
- None.
CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:
Guggenheim's Inaugural Healthcare Innovation Conference, on Tuesday, November 12th at 10:00am ET
UBS Global Healthcare Conference, on Wednesday, November 13th at 3:30pm PT
Jefferies London Healthcare Conference, on Thursday, November 21st at 2:00pm GT
A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on accesswire.com
FAQ
What investor conferences will Moderna (MRNA) attend in November 2024?
How can I watch Moderna's (MRNA) November 2024 conference presentations?
When is Moderna (MRNA) presenting at the Guggenheim Healthcare Conference 2024?
How long will Moderna's (MRNA) November 2024 conference webcasts be available for replay?
